附属北京佑安医院陈新月教授团队2017年10月在著名医学期刊Hepatology（IF:13.246）上发表论文，题目为“A potent HBsAg response in subjects with inactive HBsAg carrier treated with Pegylated-interferon Alpla”。本研究是针对非活动性HBsAg携带者进行抗病毒治疗的前瞻性、病例对照研究，结果提示非活动性HBsAg携带者经聚乙二醇干扰素治疗可获得较高HBsAg清除率，该研究第一次为非活动性HBsAg携带者的抗病毒治疗提供了有效性及安全性数据。
该文以144例非活动性HBsAg携带者为研究对象，根据病毒复制水平，分别给予聚乙二醇干扰素或聚乙二醇干扰素联合阿德福韦治疗，疗程96周，治疗组HBsAg清除率可达到44.7%，HBsAg血清学转化率为38.3%，而对照组仅分别为2.4%和0%。另外，随访结果提示，经治疗获得HBsAg血清学转换者，停药后仍可稳定维持血清学转换状态，未获得清除者停药未见病情加重。
全文链接：A Potent Hepatitis B Surface Antigen Response in Subjects With Inactive Hepatitis B Surface Antigen Carrier Treated With Pegylated-Interferon Alpha.Hepatology.2017 ,66(4)1058-1066. doi 10.1002hep.29213.pdf作者: 齐欢畅 时间: 2018-4-7 21:35
A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha
来自Wiley
收藏 引用 批量引用 报错 分享
作者 Z Cao ， Y Liu ， L Ma ， J Lu ， Y Jin ， ...
摘要Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers. There were 144 inactive HBsAg carriers enrolled and divided into a therapeutic group (102 subjects) and a control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with adefovir dipivoxil were used for treatment group subjects with hepatitis B virus DNA <20 IU/mL and 20 IU/mL ≤ hepatitis B virus DNA < 2,000 IU/mL, respectively. Total therapy duration was no more than 96 weeks. HBsAg clearance and seroconversion rates at therapeutic weeks 48 and 96 were used to evaluate the therapeutic efficacy. Per protocol analysis showed that the HBsAg clearance rate and seroconversion rate in the treatment group were 29.8% and 20.2% at week 48 and increased to 44.7% and 38.3% at week 96, respectively. However, the HBsAg clearance rate in the control group was 2.4% at weeks 48 and 96, and no subject achieved seroconversion. The quantitative HBsAg levels and changes during the early period of treatment (at week 12 and week 24) as well as the alanine aminotransferase elevation at week 12 were strong predictors of HBsAg clearance. The adverse events were similar to those with treatment for chronic hepatitis B patients. High rates of HBsAg clearance and seroconversion could be achieved by PEG-IFNα-2a-based treatments and the treatments were relatively safe for inactive HBsAg carriers. (Hepatology 2017;66:1058-1066).收起
出版源 《Hepatology》 , 2017 , 66 作者: 齐欢畅 时间: 2018-4-7 21:37
佑安医院专家研究显示
干扰素治疗可提高乙肝表面抗原转阴率
中国科技网讯（刘慧 记者李颖）最新一期的国际著名医学期刊《Hepatology》（IF:11.711分）在线发表了首都医科大学附属北京佑安医院陈新月教授团队的最新研究论文《A potent HBsAg response in subjects with inactive HBsAg carrier treated with Pegylated-interferon Alpla》。
该文以144例慢性非活动性HBsAg携带者（ALT水平正常，HBV DNA ≤2000 IU/mL，已实现HBeAg 血清学转换的慢乙肝患者）为研究对象，根据病毒复制水平，分别给予干扰素或干扰素联合阿德福韦治疗96W，研究结果提示治疗组48W及96W的HBsAg清除率分别达到29.8% 及 44.7%，HBsAg血清学转化率分别达到20.2%及 38.3%，而未干预对照组48W及96W的HBsAg清除率仅为2.4%，分析表明治疗组与对照组间统计学差异显著。该研究提示对慢性非活动性HBsAg携带者实施以干扰素为基础的抗病毒治疗可显著提高HBsAg清除/转换率，对慢性非活动性HBsAg携带者“不推荐抗病毒治疗“的观点提出了崭新的理论挑战，也为更多的病人带去了乙肝“临床治愈“的希望。
A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
(PMID:28407271)
Abstract
Citations
Related Articles
Data
BioEntities
External Links
Cao Z 1 , Liu Y 1 , Ma L 1 , Lu J 1 , Jin Y 1 , Ren S 1 , He Z 1 , Shen C 2 , Chen X 1
Affiliations
Hepatology (Baltimore, Md.) [13 Apr 2017, 66(4):1058-1066]
Type: Controlled Clinical Trial, Research Support, Non-U.S. Gov't, Journal Article
DOI: 10.1002/hep.29213 The Digital Object Identifier (DOI) System enables identification of digital entities
Abstract
Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers. There were 144 inactive HBsAg carriers enrolled and divided into a therapeutic group (102 subjects) and a control group (42 subjects). PEG-IFNα-2a and PEG-IFNα-2a combined with adefovir dipivoxil were used for treatment group subjects with hepatitis B virus DNA <20 IU/mL and 20 IU/mL ≤ hepatitis B virus DNA < 2,000 IU/mL, respectively. Total therapy duration was no more than 96 weeks. HBsAg clearance and seroconversion rates at therapeutic weeks 48 and 96 were used to evaluate the therapeutic efficacy. Per protocol analysis showed that the HBsAg clearance rate and seroconversion rate in the treatment group were 29.8% and 20.2% at week 48 and increased to 44.7% and 38.3% at week 96, respectively. However, the HBsAg clearance rate in the control group was 2.4% at weeks 48 and 96, and no subject achieved seroconversion. The quantitative HBsAg levels and changes during the early period of treatment (at week 12 and week 24) as well as the alanine aminotransferase elevation at week 12 were strong predictors of HBsAg clearance. The adverse events were similar to those with treatment for chronic hepatitis B patients.High rates of HBsAg clearance and seroconversion could be achieved by PEG-IFNα-2a-based treatments and the treatments were relatively safe for inactive HBsAg carriers. (Hepatology 2017;66:1058-1066). 作者: 爱上静 时间: 2018-4-7 22:40
